213 related articles for article (PubMed ID: 24504379)
1. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Loibl S; Volz C; Mau C; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Hanusch C; Jackisch C; Kümmel S; Huober J; Denkert C; Hilfrich J; Konecny GE; Fett W; Stickeler E; Harbeck N; Mehta KM; Nekljudova V; von Minckwitz G; Untch M
Breast Cancer Res Treat; 2014 Feb; 144(1):153-62. PubMed ID: 24504379
[TBL] [Abstract][Full Text] [Related]
2. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
6. The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.
Tamirisa N; Williamson HV; Thomas SM; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Hyslop T; Hwang ES; Fayanju OM
J Surg Oncol; 2019 Aug; 120(2):132-141. PubMed ID: 31062375
[TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
9. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
Ataseven B; Lederer B; Blohmer JU; Denkert C; Gerber B; Heil J; Kühn T; Kümmel S; Rezai M; Loibl S; von Minckwitz G
Ann Surg Oncol; 2015 Apr; 22(4):1118-27. PubMed ID: 25297900
[TBL] [Abstract][Full Text] [Related]
10. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
[TBL] [Abstract][Full Text] [Related]
11. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
Tubiana-Hulin M; Stevens D; Lasry S; Guinebretière JM; Bouita L; Cohen-Solal C; Cherel P; Rouëssé J
Ann Oncol; 2006 Aug; 17(8):1228-33. PubMed ID: 16740599
[TBL] [Abstract][Full Text] [Related]
12. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
14. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
Cristofanilli M; Gonzalez-Angulo A; Sneige N; Kau SW; Broglio K; Theriault RL; Valero V; Buzdar AU; Kuerer H; Buchholz TA; Hortobagyi GN
J Clin Oncol; 2005 Jan; 23(1):41-8. PubMed ID: 15625359
[TBL] [Abstract][Full Text] [Related]
15. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
16. Infiltrating lobular carcinoma of the breast: systemic treatment.
Farese SA; Aebi S
Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
[TBL] [Abstract][Full Text] [Related]
17. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E; Bagnardi V; Rotmensz N; Viale G; Pruneri G; Veronesi P; Cancello G; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Zurrida S; Gentilini O; Mastropasqua MG; Bottiglieri L; Iorfida M; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2010 Dec; 124(3):689-99. PubMed ID: 20625816
[TBL] [Abstract][Full Text] [Related]
18. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?
Jayasinghe UW; Bilous AM; Boyages J
Breast J; 2007; 13(5):479-85. PubMed ID: 17760669
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated?
Tsung K; Grobmyer SR; Tu C; Abraham J; Budd GT; Valente SA
Am J Surg; 2018 Mar; 215(3):509-512. PubMed ID: 29197477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]